Receptor status of breast cancer diagnosed during pregnancy: A literature review

[Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical reviews in oncology/hematology 2021-12, Vol.168, p.103494-103494, Article 103494
Hauptverfasser: Bakhuis, Carsten F.J., Suelmann, Britt B.M., van Dooijeweert, Carmen, Linn, Sabine, van der Wall, Elsken, van Diest, Paul J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 103494
container_issue
container_start_page 103494
container_title Critical reviews in oncology/hematology
container_volume 168
creator Bakhuis, Carsten F.J.
Suelmann, Britt B.M.
van Dooijeweert, Carmen
Linn, Sabine
van der Wall, Elsken
van Diest, Paul J.
description [Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients). The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.
doi_str_mv 10.1016/j.critrevonc.2021.103494
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2590135996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S104084282100281X</els_id><sourcerecordid>2590135996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwC8hLNil-JU7YlYqXVAmEYG059qRy1SbBdkD9e1y1wJLVjGbuncdBCFMypYQW16up8S56-OxaM2WE0VTmohJHaExLWWVEFPQ45USQrBSsHKGzEFaEECEKeYpGXEiac1qM0csrGOhj53GIOg4Bdw2uPegQsdGtAY-t08u2C2CxHbxrl7j3sGxTb3uDZ3jtIvhk9IDTOQ6-ztFJo9cBLg5xgt7v797mj9ni-eFpPltkhksRM24sJbKQVV1yxpksasKlzIkxTNeNAGO4rQ0wQmvRaLCa5bTUubSsqSqQjE_Q1X5u77uPAUJUGxcMrNe6hW4IiuUVoTyvqiJJy73U-C4ED43qvdtov1WUqB1PtVJ_PNWOp9rzTNbLw5ah3oD9Nf4ATILbvQDSr-l_r4JxkMBZ58FEZTv3_5ZviX2MxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2590135996</pqid></control><display><type>article</type><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</creator><creatorcontrib>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</creatorcontrib><description>[Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients). The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2021.103494</identifier><identifier>PMID: 34715316</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - epidemiology ; Estrogen receptor ; Female ; HER2 ; Humans ; Pregnancy ; Progesterone receptor ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - genetics ; Receptors, Progesterone ; Triple Negative Breast Neoplasms</subject><ispartof>Critical reviews in oncology/hematology, 2021-12, Vol.168, p.103494-103494, Article 103494</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</citedby><cites>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</cites><orcidid>0000-0002-7155-3337 ; 0000-0001-8030-4335</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S104084282100281X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34715316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bakhuis, Carsten F.J.</creatorcontrib><creatorcontrib>Suelmann, Britt B.M.</creatorcontrib><creatorcontrib>van Dooijeweert, Carmen</creatorcontrib><creatorcontrib>Linn, Sabine</creatorcontrib><creatorcontrib>van der Wall, Elsken</creatorcontrib><creatorcontrib>van Diest, Paul J.</creatorcontrib><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>[Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients). The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</description><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Estrogen receptor</subject><subject>Female</subject><subject>HER2</subject><subject>Humans</subject><subject>Pregnancy</subject><subject>Progesterone receptor</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - genetics</subject><subject>Receptors, Progesterone</subject><subject>Triple Negative Breast Neoplasms</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwC8hLNil-JU7YlYqXVAmEYG059qRy1SbBdkD9e1y1wJLVjGbuncdBCFMypYQW16up8S56-OxaM2WE0VTmohJHaExLWWVEFPQ45USQrBSsHKGzEFaEECEKeYpGXEiac1qM0csrGOhj53GIOg4Bdw2uPegQsdGtAY-t08u2C2CxHbxrl7j3sGxTb3uDZ3jtIvhk9IDTOQ6-ztFJo9cBLg5xgt7v797mj9ni-eFpPltkhksRM24sJbKQVV1yxpksasKlzIkxTNeNAGO4rQ0wQmvRaLCa5bTUubSsqSqQjE_Q1X5u77uPAUJUGxcMrNe6hW4IiuUVoTyvqiJJy73U-C4ED43qvdtov1WUqB1PtVJ_PNWOp9rzTNbLw5ah3oD9Nf4ATILbvQDSr-l_r4JxkMBZ58FEZTv3_5ZviX2MxQ</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Bakhuis, Carsten F.J.</creator><creator>Suelmann, Britt B.M.</creator><creator>van Dooijeweert, Carmen</creator><creator>Linn, Sabine</creator><creator>van der Wall, Elsken</creator><creator>van Diest, Paul J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7155-3337</orcidid><orcidid>https://orcid.org/0000-0001-8030-4335</orcidid></search><sort><creationdate>202112</creationdate><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><author>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Estrogen receptor</topic><topic>Female</topic><topic>HER2</topic><topic>Humans</topic><topic>Pregnancy</topic><topic>Progesterone receptor</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - genetics</topic><topic>Receptors, Progesterone</topic><topic>Triple Negative Breast Neoplasms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakhuis, Carsten F.J.</creatorcontrib><creatorcontrib>Suelmann, Britt B.M.</creatorcontrib><creatorcontrib>van Dooijeweert, Carmen</creatorcontrib><creatorcontrib>Linn, Sabine</creatorcontrib><creatorcontrib>van der Wall, Elsken</creatorcontrib><creatorcontrib>van Diest, Paul J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakhuis, Carsten F.J.</au><au>Suelmann, Britt B.M.</au><au>van Dooijeweert, Carmen</au><au>Linn, Sabine</au><au>van der Wall, Elsken</au><au>van Diest, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Receptor status of breast cancer diagnosed during pregnancy: A literature review</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>168</volume><spage>103494</spage><epage>103494</epage><pages>103494-103494</pages><artnum>103494</artnum><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>[Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients). The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34715316</pmid><doi>10.1016/j.critrevonc.2021.103494</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7155-3337</orcidid><orcidid>https://orcid.org/0000-0001-8030-4335</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1040-8428
ispartof Critical reviews in oncology/hematology, 2021-12, Vol.168, p.103494-103494, Article 103494
issn 1040-8428
1879-0461
language eng
recordid cdi_proquest_miscellaneous_2590135996
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Aged
Biomarkers, Tumor
Breast cancer
Breast Neoplasms - diagnosis
Breast Neoplasms - epidemiology
Estrogen receptor
Female
HER2
Humans
Pregnancy
Progesterone receptor
Receptor, ErbB-2 - genetics
Receptors, Estrogen - genetics
Receptors, Progesterone
Triple Negative Breast Neoplasms
title Receptor status of breast cancer diagnosed during pregnancy: A literature review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T21%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Receptor%20status%20of%20breast%20cancer%20diagnosed%20during%20pregnancy:%20A%20literature%20review&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Bakhuis,%20Carsten%20F.J.&rft.date=2021-12&rft.volume=168&rft.spage=103494&rft.epage=103494&rft.pages=103494-103494&rft.artnum=103494&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2021.103494&rft_dat=%3Cproquest_cross%3E2590135996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2590135996&rft_id=info:pmid/34715316&rft_els_id=S104084282100281X&rfr_iscdi=true